Publications by authors named "Pankti D Reid"
Article Synopsis
- The study aimed to compare the safety and efficacy of biologic DMARDs, specifically TNFi and IL6Ri, with conventional DMARD methotrexate (MTX) in patients with inflammatory arthritis linked to immune checkpoint inhibitors (ICI-IA).
- It included 147 patients and found that TNFi led to quicker cancer progression and faster arthritis control compared to MTX, while results for IL6Ri were less definitive.
- The conclusion suggests that while biologic DMARDs may provide faster relief from arthritis symptoms, they could also be linked to quicker cancer progression compared to traditional MTX treatment.
Importance: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm.
Objective: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.
Data Sources: Trials were identified through systematic searches of electronic databases between October 2020 and January 2021.
Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the mortality of coronavirus disease 2019 (COVID-19). The IL-6 receptor-blocking monoclonal antibody tocilizumab has been repurposed for COVID-19, but prospective trials and dose-finding studies in COVID-19 have not yet fully reported. We conducted a single-arm phase II trial of low-dose tocilizumab in nonintubated hospitalized adult patients with COVID-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) ≥ 40 mg/L.
View Article and Find Full Text PDFBackground Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking monoclonal antibody, has been repurposed for Covid-19, but prospective trials and dose-finding studies in Covid-19 are lacking. Methods We conducted a phase 2 trial of low-dose tocilizumab in hospitalized adult patients with Covid-19, radiographic pulmonary infiltrate, fever, and C-reactive protein (CRP) >= 40 mg/L who did not require mechanical ventilation.
View Article and Find Full Text PDFApplied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
Clin Pharmacol Ther
September 2020
The global pandemic of coronavirus disease 2019 (COVID-19) represents an emergent threat to the public health. Mitigation strategies have been employed to varying effect in many Western nations. Treatment strategies to effectively address COVID-19 and equitably distribute resources are needed, especially in overwhelmed hospitals.
View Article and Find Full Text PDF